Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor

BACKGROUND: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, has been clinically applied for the treatment of a variety of tumors with EGFR overexpression. A phase II clinical study of erlotinib (NCIC IND-148) for recurrent or metastatic endometrial carcinoma (EC) re...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishimura, Toshio, Nakamura, Kazuto, Yamashita, Soichi, Ikeda, Sadatomo, Kigure, Keiko, Minegishi, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682234/
https://www.ncbi.nlm.nih.gov/pubmed/26673416
http://dx.doi.org/10.1186/s12885-015-1975-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682234/
https://www.ncbi.nlm.nih.gov/pubmed/26673416
http://dx.doi.org/10.1186/s12885-015-1975-5

Ejemplares similares